Abiraterone shows promise in prostate cancer fight, Dimebon for Alzheimer’s

Wednesday, July 23, 2008

A 21-patient study has shown that the drug abiraterone can stop the testosterone that feeds prostate cancer. A larger international clinical trial is underway to test the drug before it can be deemed a "miracle drug." Also, Dimebon, once used as an antihistamine, has been found to improve cognitive abilities for Alzheimer’s patients, though researchers aren't yet sure how.
Guests: Dr. Anthony D’Amico, professor and chief of Genitourinary Radiation Oncology at Dana-Farber Cancer Institute/Brigham and Women's Hospital, and Dr. Samuel Gandy, Associate Director of the Mount Sinai Alzheimer’s Disease Research Center, and Chair of the National Medical and Scientific Advisory Council of the Alzheimer’s Association

Leave a Comment

Register for your own account so you can vote on comments, save your favorites, and more. Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm your comments. Names are displayed with all comments. We reserve the right to edit any comments posted on this site. Please read the Comment Guidelines before posting. By leaving a comment, you agree to New York Public Radio's Privacy Policy and Terms Of Use.